Acolyte and Berthold form Marketing Alliance
News Jun 05, 2006
Berthold Technologies GmbH & Co. KG will support distribution of Acolyte’s BacLite® RapiTECT range of enumeration assays in Europe and the United States.
The BacLite® range currently includes BacLite® RapiTECT GRAM NEGATIVE (GN)™ for the rapid detection and enumeration of gram negative bacterial cells and BacLite® RapiTECT Mammalian (M)™ for the rapid enumeration of mammalian cells.
The BacLite® RapiTECT assay range uses adenylate kinase (AK) as a highly sensitive marker of viable cells.
Previous research has demonstrated that AK enhances the sensitivity of cell enumeration and acts as a reliable reporter of viable cells than ATP bioluminescence.
Unlike ATP, AK is present at relatively constant levels in viable cells and can be used to count cells at very low levels due to the ADP»ATP amplification process.
This AK rapid® technology is up to 100 times more sensitive than standard ATP bioluminescence and up to 1 million times more sensitive than optical measurements.
Applications for the BacLite® RapiTECT GRAM NEGATIVE (GN)™ assay include bacterial growth and inhibition studies, anti-microbial research and a range of other microbiological, bio-processing and pharmacological applications.
The BacLite® RapiTECT MAMMALIAN (M)™ assay can be used in drug discovery, bioengineering, bio-processing and genetic research as well as many areas of academic and institution based research.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019